For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …

Introduction Pre‐analytical sample handling might affect the results of Alzheimer's disease
blood‐based biomarkers. We empirically tested variations of common blood collection and …

Synaptic dysfunction and degeneration is likely the key pathophysiology for the progression
of cognitive decline in various dementia disorders. Synaptic status can be monitored by …

Amyloid-β (Aβ) is hypothesized to facilitate the spread of tau pathology beyond the medial
temporal lobe. However, there is evidence that, independently of Aβ, age-related tau …

Biomarker testing is recommended for the accurate and timely diagnosis of Alzheimer's
disease (AD). Using illustrative case narratives we consider how cerebrospinal fluid (CSF) …